Juliana Lopes Rangel Fietto

Juliana Lopes Rangel Fietto

Auto-generated profile, based on publicly available information

Juliana Lopes Rangel Fietto

Departamento de Bioquímica e Biologia Molecular, Universidade Federal de Viçosa, Av. P. H. Rolfs, s/n, Campus Universitário, CEP: 36570-000 Viçosa, MG, Brasil

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2009 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
RSRamon F. Santos
Ramon F. Santos
MPMarcela A. S. Pôssa
Marcela A. S. Pôssa
MBMatheus S. Bastos
Matheus S. Bastos
PGPaulo Marcos da Matta Guedes
Paulo Marcos da Matta Guedes
MAMárcia R. Almeida
Márcia R. Almeida
JFJuliana L. R. Fietto
Juliana L. R. Fietto
The protozoan Trypanosoma cruzi is the causative agent of Chagas disease. There are no vaccines or effective treatment, especially in the chronic phase when most patients are diagnosed. There is a clear necessity to develop new drugs and strategies for the control and treatment of Chagas disease. Recent papers have suggested the ecto-nucleotidases (from CD39 family) from pathogenic agents as important virulence factors. In this study we evaluated the influence of Ecto-Nucleoside-Triphosphate-Diphosphohydrolase (Ecto-NTPDase) activity on infectivity and virulence of T. cruzi using both in vivo and in vitro models. We followed Ecto-NTPDase activities of Y strain infective forms (trypomastigotes) obtained during sequential sub-cultivation in mammalian cells. ATPase/ADPase activity ratios of cell-derived trypomastigotes decreased 3- to 6-fold and infectivity was substantially reduced during sequential sub-cultivation. Surprisingly, at third to fourth passages most of the cell-derived trypomastigotes could not penetrate mammalian cells and had differentiated into amastigote-like parasites that exhibited 3- to 4-fold lower levels of Ecto-NTPDase activities. To evidence the participation of T. cruzi Ecto-NTPDase1 in the infective process, we evaluated the effect of known Ecto-ATPDase inhibitors (ARL 67156, Gadolinium and Suramin), or anti-NTPDase-1 polyclonal antiserum on ATPase and ADPase hydrolytic activities in recombinant T. cruzi NTPDase-1 and in live trypomastigotes. All tests showed a partial inhibition of Ecto-ATPDase activities and a marked inhibition of trypomastigotes infectivity. Mice infections with Ecto-NTPDase-inhibited trypomastigotes produced lower levels of parasitemia and higher host survival than with non-inhibited control parasites. Our results suggest that Ecto-ATPDases act as facilitators of infection and virulence in vitro and in vivo and emerge as target candidates in chemotherapy of Chagas disease. The protozoan Trypanosoma cruzi is the causative agent of Chagas disease, an endemic zoonosis present in some countries of South and Central Americas. The World Health Organization estimates that 100 million people are at risk of acquiring this disease. The infection affects mainly muscle tissues in the heart and digestive tract. There are no vaccines or effective treatment, especially in the chronic phase when most patients are diagnosed, which makes a strong case for the development of new drugs to treat the disease. In this work we evaluate a family of proteins called Ecto-Nucleoside-Triphosphate-Diphosphohydrolase (Ecto-NTPDase) as new chemotherapy target to block T. cruzi infection in mammalian cells and in mice. We have used inhibitors and antibodies against this protein and demonstrated that T. cruzi Ecto-NTPDases act as facilitators of infection in mammalian cells and virulence factors in mice model. Two of the drugs used in this study (Suramin and Gadolinium) are currently used for other diseases in humans, supporting the possibility of their use in the treatment of Chagas disease.

1 December 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MRMichelle Peixoto Rodrigues
Michelle Peixoto Rodrigues
DTDeborah Campos Tomaz
Deborah Campos Tomaz
LSLuciana Ângelo de Souza
Luciana Ângelo de Souza
TOThiago Souza Onofre
Thiago Souza Onofre
WMWemerson Aquiles de Menezes
Wemerson Aquiles de Menezes
RTRobson Ricardo Teixeira
Robson Ricardo Teixeira

27 February 2019 in Viruses
Verified
Journal Article
Open access
PDF file
GSGiuliana Loreto Saraiva
Giuliana Loreto Saraiva
Pedro Marcus Pereira VidigalPedro Marcus Pereira Vidigal
Pedro Marcus Pereira Vidigal
VAViviane Sisdelli Assao
Viviane Sisdelli Assao
MFMurilo Leone Miranda Fajardo
Murilo Leone Miranda Fajardo
ALAlerrandra Nunes Saraiva Loreto
Alerrandra Nunes Saraiva Loreto
ASAbelardo Silva-Júnior
Abelardo Silva-Júnior
Porcine circovirus 3 (PCV3) is an emerging virus that was first identified in the United States in 2016. Since its first detection, PCV3 has already been found in America, Asia, and Europe. Although PCV3 has already been described in Brazil, knowledge of its detection and sequence variation before 2016 is limited, as well as its distribution in the main swine producing regions of Brazil. In this study, 67 porcine clinical samples collected from nine states in Brazil between 2006 and 2007 were analyzed for PCV3 infection by PCR. Results showed that 47.8% of the samples were PCV3 positive, across all nine states. Of the PCV3-positive samples, 37.5% were also positive for PCV2. Interestingly, no clinical signs were associated with samples that were detected singularly with PCV3 infection. Moreover, the positive PCV3 rate in healthy pigs was higher (29.8%) than that found in unhealthy pigs (17.9%), suggesting that most pigs could live with PCV3 infection without any clinical sign in the analyzed samples. Nucleotide sequence analysis showed that PCV3 strains obtained in this study shared 94.44% to 99.83% sequence identity at the open reading frame 2 (ORF2) gene level with available strains from different countries. PCV3 Brazilian sequences collected in 2006 and 2007 shared 97.94% to 99.62% identity with the strains obtained in 2016. The results of neutrality and selective pressure tests indicated that the PCV3 Cap protein seems unable to tolerate high levels of variation on its sequence. Phylogenetic analysis grouped the Brazilian strains in PCV3a and PCV3b genotypes clusters, both including strains collected in America, Asia, and Europe. Taking the results together, multiple events of introduction of PCV3 may have occurred in Brazil, and Brazilian PCV3 strains may show genetic stability over the past 10 years.

1 July 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RSRaoni Pais Siqueira
Raoni Pais Siqueira
MBMarcus Vinícius de Andrade Barros
Marcus Vinícius de Andrade Barros
ÉBÉverton de Almeida Alves Barbosa
Éverton de Almeida Alves Barbosa
TOThiago Souza Onofre
Thiago Souza Onofre
VGVictor Hugo Sousa Gonçalves
Victor Hugo Sousa Gonçalves
GBGustavo Costa Bressan
Gustavo Costa Bressan

13 November 2014 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
RVRaphael De Souza Vasconcellos
Raphael De Souza Vasconcellos
CMChristiane Mariotini-Moura
Christiane Mariotini-Moura
RGRodrigo Saar Gomes
Rodrigo Saar Gomes
TSTiago Donatelli Serafim
Tiago Donatelli Serafim
RFRafaela De Cássia Firmino
Rafaela De Cássia Firmino
JFJuliana Lopes Rangel Fietto
Juliana Lopes Rangel Fietto
Visceral leishmaniasis is an important tropical disease, and Leishmania infantum chagasi (synonym of Leishmania infantum) is the main pathogenic agent of visceral leishmaniasis in the New World. Recently, ecto-nucleoside triphosphate diphosphohydrolases (E-NTPDases) were identified as enablers of infection and virulence factors in many pathogens. Two putative E-NTPDases (∼70 kDa and ∼45 kDa) have been found in the L. infantum genome. Here, we studied the ∼45 kDa E-NTPDase from L. infantum chagasi to describe its natural occurrence, biochemical characteristics and influence on macrophage infection. We used live L. infantum chagasi to demonstrate its natural ecto-nucleotidase activity. We then isolated, cloned and expressed recombinant rLicNTPDase-2 in bacterial system. The recombinant rLicNTPDase-2 hydrolyzed a wide variety of triphosphate and diphosphate nucleotides (GTP> GDP = UDP> ADP> UTP = ATP) in the presence of calcium or magnesium. In addition, rLicNTPDase-2 showed stable activity over a pH range of 6.0 to 9.0 and was partially inhibited by ARL67156 and suramin. Microscopic analyses revealed the presence of this protein on cell surfaces, vesicles, flagellae, flagellar pockets, kinetoplasts, mitochondria and nuclei. The blockade of E-NTPDases using antibodies and competition led to lower levels of parasite adhesion and infection of macrophages. Furthermore, immunohistochemistry showed the expression of E-NTPDases in amastigotes in the lymph nodes of naturally infected dogs from an area of endemic visceral leishmaniasis. In this work, we cloned, expressed and characterized the NTPDase-2 from L. infantum chagasi and demonstrated that it functions as a genuine enzyme from the E-NTPDase/CD39 family. We showed that E-NTPDases are present on the surface of promastigotes and in other intracellular locations. We showed, for the first time, the broad expression of LicNTPDases in naturally infected dogs. Additionally, the blockade of NTPDases led to lower levels of in vitro adhesion and infection, suggesting that these proteins are possible targets for rational drug design. Visceral leishmaniasis is a dangerous and important, but neglected, tropical disease that affects millions of people, mainly in underdeveloped and developing countries. Presently, there are no vaccines against Leishmaniasis, and the few drugs with which the disease is treated have low efficacy and high side effects. The pathogenic agent of this disease in the New World is Leishmania infantum chagasi. In this work, we studied a protein from this parasite named ENTPDase-2. We expressed it in a bacterial system, purified it and characterized it as a genuine nucleotidase of the ENTPDase family. This protein seems to be localized at the surface of the parasite and in other intracellular locations. ENTPDase seems to facilitate in vitro infection because its blockade leads to lower levels of infection of macrophages. In addition, the protein is found in naturally infected dogs. A previous study demonstrated that ENTPDase-2 from L. infantum chagasi is a good antigen for immunodiagnosis of canine visceral leishmaniasis. We have now studied this protein in greater depth and suggest that it may be a good target for drug development.

1 December 2019 in Process Biochemistry
Verified
Journal Article
Closed access
TOTatiana Aparecida de Oliveira
Tatiana Aparecida de Oliveira
WSWalmir da Silva
Walmir da Silva
NTNancy da Rocha Torres
Nancy da Rocha Torres
JMJoão Victor Badaró de Moraes
João Victor Badaró de Moraes
RSRenato Lima Senra
Renato Lima Senra
JFJuliana Lopes Rangel Fietto
Juliana Lopes Rangel Fietto